Immunogenicity and protective effect of a DNA construct encoding certain neutralizing epitopes of herpes simplex virus type-1 glycoprotein B

Department of Virology, School of Medical Sciences, Tarbiat Modarres University, Tehran, Iran.
Folia biologica (Impact Factor: 1). 02/2005; 51(4):109-13.
Source: PubMed


Much attention is presently focused on the vaccination with certain epitopes of an antigen. To further study the ability of neutralizing epitopes mapped in the first 1515 nucleotides of glycoprotein B of herpes simplex virus type-1 (gB-1) to induce neutralizing antibodies, a DNA immunization approach was employed. Vaccination of mice with a plasmid expressing the neutralizing epitopes induced humoral immune responses, although the antibody titre was significantly lower than that of antibodies induced by the full-length gB-1 gene. Furthermore, the plasmid DNA could not protect the mice against HSV-1 lethal challenge, but could significantly prolong the survival time compared to mock-vaccinated group.

Download full-text


Available from: Hoorieh Soleimanjahi,
  • Source
    • "Wild HSV-1 was isolated from a cold sore lesion of a patient. The virus was confirmed as HSV-1 with an HSV-1 by IFA using HSV-1 specific monoclonal antibody [33]. The neurovirulence of the virus was proven by injection of the virus into mice and isolation of the virus from brains of dead mice. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The immunomodulatory effects of exogenous opioids on induction of acquired immunity during microbial infection are now well known; however, our knowledge about the relationship between endogenous opioid response and microbial infections is rudimentary. Here, we report the effect of administration of Naloxone (NLX), an opioid receptor antagonist, on induction of acquired immunity during primary herpes simplex virus type 1 (HSV-1) infection. BALB/c mice received NLX, twice daily, 2 h before infection with HSV-1 until 7 days after infection. Cell-mediated immunity was assessed by evaluating lymphocyte proliferation, interferon-gamma (IFN-gamma) production, delayed type hypersensitivity (DTH) and mortality rate after acute HSV-1 challenge. The findings showed that a higher level of cell-mediated immunity was induced in the NLX-treated animals compared to the control group after induction of HSV-1 infection. However, the data indicate similar neutralizing antibody production in NLX-treated animals and control animals. This observation and further studies in this field may lead to the use of NLX as an adjuvant for designing microbial vaccines and adjunctive therapy of viral infections.
    Microbial Pathogenesis 11/2007; 43(5-6):217-23. DOI:10.1016/j.micpath.2007.06.001 · 1.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The vast majority of the world’s population is infected with Herpes simplex virus (HSV). Although antiviral therapy can reduce the incidence of reactivation and asymptomatic viral shedding and limits morbidity and mortality from active disease, it cannot cure infection. Therefore, the development of an effective vaccine is an important global health priority. In this study, the induction of IFN-γ production was compared in different herpes simplex virus 1 (HSV-1) vaccines. Glycoprotein D (gD1) as a major immunogenic HSV-1 glycoprotein was chosen to our study. Balb/c mice were administered with DNA vaccine encoding gD1, subunit glycoprotein vaccine including insect cells infected by a gD1 recombinant Baculovirus, prime DNA vaccine boosted by subunit glycoprotein vaccine, inactivated KOS strain as a positive control, pcDNA3 plasmid and Sf9 cells as negative controls. Evaluation tests showed that the amount of IFN-γ mRNA at 8, 16 and 32 hours after restimulation sharply decreased whereas, the IFN-γ protein level is significantly increased. Our results revealed that at 14 days after immunization IFN-γ secretion of stimulated cells in all of the vaccinated groups dramatically raised rather than secreted IFN-γ levels in mice that were analyzed at 7 days after vaccination. In comparison to other groups; Prime-Boost immunization dramatically caused vigorous and prompt IFN-γ production at 7 days after immunization and 8 hours after restimulation.
    Molecular Biology 06/2009; 43(3):388-393. DOI:10.1134/S0026893309030066 · 0.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Recent research on several DNA fragments covering open reading frames (ORF) 1-37 shows a new genetic marker in ORF 6 which is specific for differentiating wild-type varicella-zoster virus (VZV) strains from Oka varicella vaccine strain. On the other hand, herpes simplex virus (HSV) genome analysis by restriction enzymes is used to differentiate types one and two of the virus and even strains of each type. Previous studies using PCR-sequencing technique have shown that the thymidine kinase (TK) gene of HSV-1 is polymorphic. Methods: In this study, TK gene and DNA binding protein (UL29) gene of HSV-1 were selected. Both genes were analyzed with restriction endonucleases in order to identify a genetic marker for differentiating native strains of HSV-1 from the foreign strain. Three isolates of HSV-1 as well as standard strain of KOS were propagated in Vero cells. Initially, a pair of specific primers for each gene was designed to amplify UL29 and TK genes of these isolates. Subsequently, PCR products of these genes were digested separately with five restriction enzymes and subjected to polyacrylamide gel electrophoresis. Results: Using PCR-RFLP (Restriction fragment length polymorphisms) technique, results indicate that the patterns of restriction endonuclease digestion of UL29 and TK genes of the three isolates show no differences when compared to KOS strain. Conclusion: The genotypes of Iranian isolates are the same as KOS genotype and both genotypes are derived from a common ancestor. Hence, it can be postulated that in the process of random population flow among Iran, Europe and USA, the original KOS strain infected the Iranian population at some point in time. Iran. Biomed. J. 10 (3): 157-161, 2006
    Iranian biomedical journal 01/2006; 10(3).
Show more